A phase I study of the heparanase inhibitor: PI-88 and weekly docetaxel in patients (PTS) with advanced solid malignancies.

被引：0
|
作者：
Raj, SKS
Basche, M
Gore, L
Grolnic, S
Hunt, J
O'Bryant, CL
Morrow, M
Creese, B
Kangas, M
Sawlwin, D
Eckhardt, SG
Holden, SN
Holden, SN
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Progen Ind Ltd, Darra, Australia
[3] Omnicare Clin Res, Sydney, NSW, Australia
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6152S / 6152S
页数：1
相关论文
共 50 条
  • [1] A phase I study of the heparanase inhibitor PI-88 given subcutaneously (SQ) in patients (pts) with advanced solid malignancies.
    Basche, M
    Eckhardt, SG
    O'Bryant, CL
    Gore, L
    Witta, S
    Raj, S
    Schultz, MK
    Persky, M
    Morrow, M
    Grolnic, S
    Hunt, JE
    Creese, B
    Kangas, M
    Roberts, K
    Sawlwin, D
    Moore, J
    Holden, SN
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6140S - 6140S
  • [2] A phase I study of the heparanase inhibitor PI-88 given subcutaneously (sq) in patients (pts) with advanced solid malignancies
    Holden, S
    Basche, M
    O'Bryant, C
    Morrow, M
    Grolnic, S
    Persky, M
    Deem, C
    Roberts, K
    Ribbons, K
    Eckhardt, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S74 - S75
  • [3] A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors
    Basche, Michele
    Gustafson, Daniel L.
    Holden, Scott N.
    O'Bryant, Cindy L.
    Gore, Lia
    Witta, Samir
    Schultz, Mary Kay
    Morrow, Mark
    Levin, Adrah
    Creese, Brian R.
    Kangas, Michael
    Roberts, Kaye
    Nguyen, Thu
    Davis, Kat
    Addison, Russell S.
    Moore, Jane C.
    Eckhardt, S. Gail
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5471 - 5480
  • [4] A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
    Laura Q. M. Chow
    Daniel L. Gustafson
    Cindy L. O’Bryant
    Lia Gore
    Michele Basche
    Scott N. Holden
    Mark C. Morrow
    Stacy Grolnic
    Brian R. Creese
    Kaye L. Roberts
    Kat Davis
    Russell Addison
    S. Gail Eckhardt
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 65 - 74
  • [5] A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
    Chow, Laura Q. M.
    Gustafson, Daniel L.
    O'Bryant, Cindy L.
    Gore, Lia
    Basche, Michele
    Holden, Scott N.
    Morrow, Mark C.
    Grolnic, Stacy
    Creese, Brian R.
    Roberts, Kaye L.
    Davis, Kat
    Addison, Russell
    Eckhardt, S. Gail
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 65 - 74
  • [6] A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma
    Karl D. Lewis
    William A. Robinson
    Michael J. Millward
    Alex Powell
    Timothy J. Price
    Damien B. Thomson
    Euan T. Walpole
    Andrew M. Haydon
    Brian R. Creese
    Kaye L. Roberts
    John R. Zalcberg
    Rene Gonzalez
    Investigational New Drugs, 2008, 26 : 89 - 94
  • [7] A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma
    Lewis, Karl D.
    Robinson, William A.
    Millward, Michael J.
    Powell, Alex
    Price, Timothy J.
    Thomson, Damien B.
    Walpole, Euan T.
    Haydon, Andrew M.
    Creese, Brian R.
    Roberts, Kaye L.
    Zalcberg, John R.
    Gonzalez, Rene
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 89 - 94
  • [8] Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
    Khasraw, M.
    Pavlakis, N.
    McCowatt, S.
    Underhill, C.
    Begbie, S.
    de Souza, P.
    Boyce, A.
    Parnis, F.
    Lim, V.
    Harvie, R.
    Marx, G.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1302 - 1307
  • [9] A phase II trial of PI-88, a novel antiangiogenic and antimetastatic heparanase inhibitor, in patients with advanced melanoma.
    Thomson, DB
    Gonzalez, R
    Millward, M
    Price, T
    Haydon, A
    Robinson, W
    Powell, A
    Roberts, K
    Creese, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 724S - 724S
  • [10] A phase I combination study of irofulven (IROF) and gemcitabine (GEM) in patients (pts) with advanced solid malignancies.
    O'Bryant, CL
    Gore, L
    Long, M
    Gustafson, D
    Eppers, S
    Basche, M
    Rothenberg, M
    Weems, G
    Shah, A
    Herdrich, L
    Eckhardt, SG
    Berlin, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9119S - 9120S
12345